Trial Shows Micardis(R) (telmisartan) Reduces The Risk Of Cardiovascular Death, Heart Attack And Stroke In ACE-Intolerant High-Risk Patients Part 4

Astellas Pharma Inc. co-promotes telmisartan below the trademark Micardis®, Bayer HealthCare promote telmisartan under the heap scorn against name Kinzalmono®, Kinzalkomb® (combination subsequent to hydrochlorothiazide), and Pritor® and PritorPlus® (combination with hydrochlorothiazide) contained via marketplace across Europe. Pritor®, and PritorPlus® be also market by GlaxoSmithKline in special markets.

The promoter of the ONTARGET® Trial Programme is Boehringer Ingelheim; co-funders in selected country be Bayer HealthCare and GlaxoSmithKline.

Boehringer Ingelheim The Boehringer Ingelheim squadron is one of the world's 20 influential pharmaceutical company. Headquartered in Ingelheim, Germany, it operate overall with 135 affiliate in 47 countries and 39,800 workforce. Since it be found in 1885, the family-owned ancestors own be committed to research, growing, industrial and marketing advanced products of elevated medical warrant in desire of human and veterinary tablets.

In 2007, Boehringer Ingelheim rearrangement trellis sale of 10.9 billion euro while outgoings one fifth of net sales in its largest company segment Prescription Medicines on research and fostering.

Related links: Boehringer Ingelheim grit pack - European Society of Cardiology Congress 2008 (ESC)Ontarget-Telmisartan website (for Healthcare Professionals shell the U.S. only)Micardis® website (for Healthcare Professionals outside the U.S. only) References: 1. The TRANSCEND Investigators. Effects of the angiotensin-receptor blocker telmisartan on cardiovascular torment in high-risk patients remorseless to angiotensin-converting enzyme inhibitors: a randomized controlled trial. Lancet Published online 31 August 2008.

2.The Heart Outcomes Prevention Evaluation Study Investigators. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med 2000; 342:145-53.

3. The ONTARGET investigators. Telmisartan, ramipril, or both in patients at high speculate for vascular events. N Eng J Med 2008; 358(15):1547-59.

4. Israili ZH, Hall WD. Cough and angioedema associated with angiotensin-coverting enzyme inhibitor psychiatric sustain. A revision of the literature and pathophysiology. Ann Intern Med 1992; 117(3):234-42.

5.Matchar DB, et al. Systematic Review: Comparative entrance excise of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers for oversupply vital hypertension.

Ann Intern Med 2008; 148:16-29.

6. Macaulay TE, Dunn SP. Cross-reactivity of ACE-inhibitor-induced angioedema with ARBs. US Pharmacist 2007; 32 (2).

7. World Health Organization, Fact Sheet 317: Cardiovascular Diseases February 2007. (Accessed August 2008) 8. Murray CJL, Lopez AD. eds. The Global Burden of Disease: A absolute review of mortality and disability from virus, injury, and risk factor in 1990 and projected to 2020.

Cambridge; Harvard University Press 2001.

9. Primary Prevention of Ischemic Stroke. A Guideline from the American Heart Association/American Stroke Association Stroke Council. Stroke 2006; 37:1583-1633.

Boehringer Ingelheim

You can buy acomplia online for you health.